BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 31849039)

  • 1. Identification of an HLA-A*24:02-restricted α-fetoprotein signal peptide-derived antigen and its specific T-cell receptor for T-cell immunotherapy.
    Li Z; Gong H; Liu Q; Wu W; Cheng J; Mei Y; Chen Y; Zheng H; Yu X; Zhong S; Li Y
    Immunology; 2020 Apr; 159(4):384-392. PubMed ID: 31849039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of alpha-fetoprotein-derived peptides recognized by cytotoxic T lymphocytes in HLA-A24+ patients with hepatocellular carcinoma.
    Mizukoshi E; Nakamoto Y; Tsuji H; Yamashita T; Kaneko S
    Int J Cancer; 2006 Mar; 118(5):1194-204. PubMed ID: 16152611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of α-fetoprotein-specific T-cell receptors for hepatocellular carcinoma immunotherapy.
    Zhu W; Peng Y; Wang L; Hong Y; Jiang X; Li Q; Liu H; Huang L; Wu J; Celis E; Merchen T; Kruse E; He Y
    Hepatology; 2018 Aug; 68(2):574-589. PubMed ID: 29443377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selection of a Clinical Lead TCR Targeting Alpha-Fetoprotein-Positive Liver Cancer Based on a Balance of Risk and Benefit.
    Luo X; Cui H; Cai L; Zhu W; Yang WC; Patrick M; Zhu S; Huang J; Yao X; Yao Y; He Y; Ji Y
    Front Immunol; 2020; 11():623. PubMed ID: 32425926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Alpha-Fetoprotein (AFP)-MHC Complex with CAR T-Cell Therapy for Liver Cancer.
    Liu H; Xu Y; Xiang J; Long L; Green S; Yang Z; Zimdahl B; Lu J; Cheng N; Horan LH; Liu B; Yan S; Wang P; Diaz J; Jin L; Nakano Y; Morales JF; Zhang P; Liu LX; Staley BK; Priceman SJ; Brown CE; Forman SJ; Chan VW; Liu C
    Clin Cancer Res; 2017 Jan; 23(2):478-488. PubMed ID: 27535982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tuning T-Cell Receptor Affinity to Optimize Clinical Risk-Benefit When Targeting Alpha-Fetoprotein-Positive Liver Cancer.
    Docta RY; Ferronha T; Sanderson JP; Weissensteiner T; Pope GR; Bennett AD; Pumphrey NJ; Ferjentsik Z; Quinn LL; Wiedermann GE; Anderson VE; Saini M; Maroto M; Norry E; Gerry AB
    Hepatology; 2019 May; 69(5):2061-2075. PubMed ID: 30561769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between High-Avidity T-Cell Receptors, Induced by α-Fetoprotein-Derived Peptides, and Anti-Tumor Effects in Patients With Hepatocellular Carcinoma.
    Nakagawa H; Mizukoshi E; Kobayashi E; Tamai T; Hamana H; Ozawa T; Kishi H; Kitahara M; Yamashita T; Arai K; Terashima T; Iida N; Fushimi K; Muraguchi A; Kaneko S
    Gastroenterology; 2017 May; 152(6):1395-1406.e10. PubMed ID: 28188748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
    Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
    Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma.
    Mizukoshi E; Nakamoto Y; Arai K; Yamashita T; Sakai A; Sakai Y; Kagaya T; Yamashita T; Honda M; Kaneko S
    Hepatology; 2011 Apr; 53(4):1206-16. PubMed ID: 21480325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
    Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH
    Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of HLA-A24 restricted shared antigen recognized by autologous cytotoxic T lymphocytes from a patient with large cell carcinoma of the lung.
    Sugaya M; Takenoyama M; Shigematsu Y; Baba T; Fukuyama T; Nagata Y; Mizukami M; So T; Ichiki Y; Yasuda M; So T; Hanagiri T; Sugio K; Yasumoto K
    Int J Cancer; 2007 Mar; 120(5):1055-62. PubMed ID: 17131342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of dendritic-based vaccine efficacy against hepatitis B virus-related hepatocellular carcinoma by two tumor-associated antigen gene-infected dendritic cells.
    Yang JY; Cao DY; Xue Y; Yu ZC; Liu WC
    Hum Immunol; 2010 Mar; 71(3):255-62. PubMed ID: 20036295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
    Komori H; Nakatsura T; Senju S; Yoshitake Y; Motomura Y; Ikuta Y; Fukuma D; Yokomine K; Harao M; Beppu T; Matsui M; Torigoe T; Sato N; Baba H; Nishimura Y
    Clin Cancer Res; 2006 May; 12(9):2689-97. PubMed ID: 16675560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fine specificity analysis of an HLA-A2.1-restricted immunodominant T cell epitope derived from human alpha-fetoprotein.
    Meng WS; Butterfield LH; Ribas A; Heller JB; Dissette VB; Glaspy JA; McBride WH; Economou JS
    Mol Immunol; 2000 Nov; 37(16):943-50. PubMed ID: 11395133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a T-cell receptor multimer with high avidity for detecting a naturally presented tumor-associated antigen on osteosarcoma cells.
    Watanabe K; Tsukahara T; Toji S; Saitoh S; Hirohashi Y; Nakatsugawa M; Kubo T; Kanaseki T; Kameshima H; Terui T; Sato N; Torigoe T
    Cancer Sci; 2019 Jan; 110(1):40-51. PubMed ID: 30375705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein.
    Butterfield LH; Meng WS; Koh A; Vollmer CM; Ribas A; Dissette VB; Faull K; Glaspy JA; McBride WH; Economou JS
    J Immunol; 2001 Apr; 166(8):5300-8. PubMed ID: 11290817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Artificial antigen-presenting cells expressing AFP(158-166) peptide and interleukin-15 activate AFP-specific cytotoxic T lymphocytes.
    Sun L; Guo H; Jiang R; Lu L; Liu T; Zhang Z; He X
    Oncotarget; 2016 Apr; 7(14):17579-90. PubMed ID: 27007051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lentivirally engineered dendritic cells activate AFP-specific T cells which inhibit hepatocellular carcinoma growth in vitro and in vivo.
    Liu Y; Butterfield LH; Fu X; Song Z; Zhang X; Lu C; Ding G; Wu M
    Int J Oncol; 2011 Jul; 39(1):245-53. PubMed ID: 21491085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineered cytotoxic T lymphocytes with AFP-specific TCR gene for adoptive immunotherapy in hepatocellular carcinoma.
    Sun L; Guo H; Jiang R; Lu L; Liu T; He X
    Tumour Biol; 2016 Jan; 37(1):799-806. PubMed ID: 26250457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24.
    Tanaka F; Fujie T; Tahara K; Mori M; Takesako K; Sette A; Celis E; Akiyoshi T
    Cancer Res; 1997 Oct; 57(20):4465-8. PubMed ID: 9377553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.